Panel: Drug plan experts call for balance between cost and value

As the drug plan landscape evolves, the nuanced tension between cost management and the imperative to support employee health continues.

Read session coverage

Preserving private drug plan coverage in Canada

As Canada navigates the evolving drug coverage landscape, private drug plans remain a cornerstone of access, innovation and economic growth.

Read session coverage

The rising impact of chronic skin conditions on drug plans

As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors.

Read session coverage

Navigating coverage challenges for GLP-1 drugs beyond weight management

A single drug can be approved for multiple conditions, but each new use requires its own clinical trials and regulatory approval, even if the drug is already approved for other indications.

This session was made possible by Novo Nordisk Canada.

Read session coverage

Pharmacy benefit managers delivering ‘operational backbone’ in drug plan management

Pharmacy benefit managers in Canada have undergone a significant transformation over the years.

Read session coverage

Closing the gap between vaccines and health benefits plans

“Immunization is one of the best investments money can buy, according to the World Health Organization.”

This session was made possible by GSK, Merck and Pfizer Canada.

Read session coverage

Multiple medication options leads to better outcomes for migraine patients

Although many medications may seem alike, in the management of chronic conditions, it’s crucial to have access to a broad selection of treatment options to achieve the most favourable outcomes for patients, since each medication can serve a distinct and important purpose for different individuals.

This session was made possible by Lundbeck.

Read session coverage

Employers urged to champion cancer support in the workplace

For Jocelyn Laidlaw, a former anchor at CTV News, a sudden diagnosis of stage 3A metastatic colorectal cancer revealed not only the emotional toll of cancer but also the systemic gaps in Canadian health care and workplace benefits.

This session was made possible by AstraZeneca Canada.

Read session coverage